Key Takeaways
- A new fusion protein called CasPER enhances the precision of the CRISPR-Cas9 gene-editing system, making cancer therapies safer.
- Initial tests show CasPER can edit genes nearly four times more effectively with significantly fewer off-target modifications compared to traditional methods.
- The technology aims to improve therapies for blood cancers and genetic disorders, with a provisional patent filed in Australia.
Advancements in Gene Editing for Cancer Treatment
Researchers at the University of Queensland have made a significant breakthrough in gene-editing technology that could lead to safer and more effective cancer therapies. Led by Dr Giovanni Pietrogrande and Dr Tahmina Tabassum, the team developed a novel fusion protein aimed at enhancing the widely used CRISPR-Cas9 system.
While CRISPR-Cas9 has revolutionized gene editing with its precision and efficiency, it is not without risks. Dr Tabassum highlighted that unintended gene mutations can occur due to incorrect DNA cuts, leading to genomic instability. This presents a potential threat in ex-vivo therapies, such as CAR-T and CAR-NK, where the patient’s immune cells are modified to target cancer cells. These mutations can reduce treatment effectiveness or activate oncogenes.
To tackle this problem, the researchers focused on creating CasPER, a clinically translatable gene-editing technology designed to improve the precision of DNA cuts while also promoting proper DNA repair mechanisms. Dr Tabassum pointed out that existing enhancements for CRISPR-Cas9 tend to improve efficiency but often don’t prioritize safety. In contrast, CasPER aims to balance both aspects, rendering it a safer option for clinical applications.
Early tests show that CasPER outperforms traditional CRISPR methods, achieving a precision-editing score almost four times higher and a dramatic ten-fold reduction in off-target gene modifications. This reduction in mutation burden is essential for developing safer cell therapy products.
Dr Tabassum underscored the potential impact of CasPER, stating it can lead to improved CAR therapies specifically for blood cancers. Beyond cancer treatment, CasPER also holds promise for addressing various genetic disorders, including rare diseases like sickle cell anemia and thalassemia.
To further develop this innovative technology, the team is actively seeking licensing and partnership opportunities. CasPER is currently protected by an Australian provisional patent filed in June 2025, backed by UniQuest, UQ’s commercialization arm.
As biotechnology continues to evolve, advancements like CasPER could pave the way for more effective and safer treatments, transforming the landscape of gene therapy and disease management.
The content above is a summary. For more details, see the source article.